Timolol-pilocarpine combined vs timolol and pilocarpine given separately

Area of Science:

• Ophthalmology
• Clinical Pharmacology

Background:

• Open-angle glaucoma management often involves multiple medications to control intraocular pressure (IOP).
• Timolol 0.5% and pilocarpine 4% are established treatments for glaucoma.
• Optimizing dosing regimens can improve patient adherence and therapeutic outcomes.

Purpose of the Study:

• To compare the efficacy and safety of a fixed combination of timolol 0.5% and pilocarpine 4% administered twice daily.
• To evaluate this fixed combination against a regimen of separate timolol 0.5% twice daily and pilocarpine 4% three times daily.

Main Methods:

• A controlled, double-observer, multicenter study.
• Involved 80 patients with open-angle glaucoma and elevated IOP despite timolol 0.5% monotherapy.
• Compared a fixed timolol-pilocarpine combination (bid) with separate timolol (bid) and pilocarpine (tid) administration.

Main Results:

• The fixed combination of timolol 0.5% and pilocarpine 4% twice daily achieved IOP reduction comparable to the separate drug regimen.
• No statistically significant differences in IOP reduction were observed between the two treatment groups.
• No unexpected adverse effects were reported for either treatment arm.

Conclusions:

• A fixed combination of timolol 0.5% and pilocarpine 4% given twice daily is an effective and safe alternative for managing open-angle glaucoma.
• This fixed-dose combination offers a potentially simpler treatment regimen compared to multiple daily administrations of separate eye drops.
• The findings support the use of fixed-combination therapy to enhance glaucoma treatment adherence and efficacy.